Stoke Therapeutics Q2 2024 Earnings Report
Key Takeaways
Stoke Therapeutics reported revenue of $4.8 million and a net loss of $25.7 million for the second quarter of 2024. The FDA removed the Partial Clinical Hold as the company advances toward a Phase 3 registrational study of zorevunersen.
FDA removed Partial Clinical Hold on zorevunersen.
Company plans to share data from Phase 1/2a and OLE studies of zorevunersen at the 15th European Epilepsy Congress in September 2024.
Company is on track to provide a regulatory update on Phase 3 registrational plans for zorevunersen in the second half of 2024.
Company is on track to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) this year.
Stoke Therapeutics
Stoke Therapeutics
Forward Guidance
The company plans to share previously presented positive data from patients treated in the Phase 1/2a and open label extension (OLE) studies of zorevunersen in children and adolescents with Dravet syndrome at the 15th European Epilepsy Congress (EEC), September 7 – 11, 2024, in Rome, Italy. The company is on track to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) this year.
Positive Outlook
- Company plans to share data from Phase 1/2a and OLE studies of zorevunersen at the 15th European Epilepsy Congress in September 2024.
- Company is on track to provide a regulatory update on Phase 3 registrational plans for zorevunersen in the second half of 2024.
- Company is on track to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) this year.